ClinicalTrials.gg
RecruitingNCT05320835OasisUpdated May 22, 2026

A Setting Focus Overdose Prevention Intervention

An interventional study of HIV, HCV and overdose prevention in HIV Infections, HCV and Drug Overdose, sponsored by Johns Hopkins Bloomberg School of Public Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health — 1 open to participants now, 1 under way, none of them phase 3. HIV Infections · Johns Hopkins Bloomberg School of Public Health.

Planned enrollment
8th of 19
285 · median 234
Started
2022
with 1 other
No phase
8 of 21
1 open now
Registered
17th of 21
by date

Among the 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health, this one is the 8th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 with no phase, and was the 17th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in HIV Infections by Johns Hopkins Bloomberg School of Public Health, or all of them as a file.
02

Study summary

A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).

Read the detailed description

This is a pilot of an injection setting targeted peer-driven intervention to reduce HIV/HCV transmission and overdose risk behaviors. Participants will be randomized to conditions: 1) Peer education and stocking of semi-public injection settings (SPIS) with risk reduction materials, and the standard of care. Based on their SPIS use, 120 index PWID participants will be selected.

A conceptual model for the intervention: The conceptual model is based on social influence, social network, and social cognitive theory. The prior work delineated social influence mechanisms. It is expected that training and modeling of effective communication skills will increase the occurrence of conversations on HIV/HCV and overdose prevention. These conversations will then alter perceived descriptive and prescriptive social norms of risk behaviors. The prior work is being enhanced by increasing the availability of risk reduction materials as well as the cuing and modeling risk reduction behaviors in risk settings. It has been found that PWID are motivated to conduct peer education; it enhances their status and provides them a prosocial role in the community. It is hypothesized that peer outreach and supply of materials to SPIS will lead to reduced sharing of injection equipment and increased naloxone availability.

03

Conditions studied

  • HIV Infections
  • HCV
  • Drug Overdose
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current drug user (opioid use in the prior two weeks)

Exclusion criteria

Exclusion Criteria:

  • Any mental or physical health impairment that impedes ability to participate
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Experimental

    behavioral training with 6 sessions

    Behavioral: HIV, HCV and overdose prevention

  • Active comparator
    comparison

    Attention control

    Behavioral: HIV, HCV and overdose prevention

Interventions

  • BehavioralHIV, HCV and overdose prevention

    HIV, HCV and overdose prevention

06

What researchers measure

Primary outcomes

  1. Overdose prevention

    Frequency of carrying naloxone

    Time frame: 6 months

  2. HIV/HCV prevention

    Frequency of using used cookers

    Time frame: 6 months

Secondary outcomes

  1. Overdose behaviors

    Frequency of testing drugs before using

    Time frame: 6 months

  2. Overdose behaviors 2

    Frequency of talking about overdose prevention

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Lighthouse Studies at Peer Point
    Baltimore, Maryland 21205, United States
    Recruiting
    • Carl Latkin, PhD · Contactcarl.latkin@jhu.edu · 410-502-5368
    • Melissa Davey-Rothwell, PhD · Contactmdavey1@jhu.edu · 410-614-5854
    • Carl Latkin, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 55 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Apr 11, 2022
StartActual
Apr 30, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
May 30, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05320835
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Apr 30, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
May 30, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Carl Latkin, PhD
Contact
carl.latkin@jhu.edu
410-955-3972
Lauren Dayton, PhD
Contact
ldayton2@jhu.edu
4105025368
Carl Latkin, PhD
principal investigator · Johns Hopkins Bloomberg School of Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion